Celldex stock price target maintained at $50 by H.C. Wainwright

H.C. Wainwright reiterated its Buy rating and $50.00 price target on Celldex Therapeutics (NASDAQ:CLDX) following the company’s presentation of 76-week data from its Phase 2 trial of barzolvolimab in chronic spontaneous urticaria (CSU). According to InvestingPro data, analyst targets for CLDX range from $31 to $90, with a strong consensus recommendation of 1.4 (Strong Buy).

The data, presented at the European Academy of Allergy and Clinical Immunology ’25 conference, showed that the benefits of barzolvolimab continued through 76 weeks of treatment. This extends the previously reported 52-week data that had demonstrated significant improvements in CSU and quality of life measures. InvestingPro analysis shows the company maintains a FAIR financial health rating, with notably strong liquidity as it holds more cash than debt on its balance sheet.

H.C. Wainwright noted that the extended results further support the long-term efficacy and durability of barzolvolimab as a treatment option for CSU patients. The research firm highlighted several key data points from the presentation as particularly noteworthy for investors.

Barzolvolimab, often referred to as barzo, is Celldex’s investigational therapy targeting mast cells, which play a central role in allergic and inflammatory conditions like CSU. The condition causes recurring hives and itching without an identifiable external trigger.

The maintained price target represents the research firm’s continued confidence in Celldex’s clinical development program and the potential market opportunity for barzolvolimab in treating chronic spontaneous urticaria.

In other recent news, Celldex Therapeutics announced impressive long-term data from its Phase 2 study of barzolvolimab for chronic spontaneous urticaria (CSU), showing sustained efficacy and a well-tolerated safety profile. The study revealed that 41% of patients reported a complete response at the 76-week mark, with 48% noting their disease no longer affected their quality of life. Analysts from HC Wainwright and Citi have positively remarked on these results, with Citi’s David Lebowitz maintaining a buy rating on Celldex. Additionally, Cantor Fitzgerald reiterated its Overweight rating and $67.00 price target, citing the unprecedented nature of the CSU therapy study. Canaccord Genuity also maintained its Buy rating and $64.00 price target, expressing optimism about the upcoming presentation of further clinical trial data. Furthermore, Celldex appointed Denice M. Torres to its Board of Directors, bringing extensive experience from her previous roles in the pharmaceutical and consumer healthcare sectors. Cantor Fitzgerald also highlighted the growing eosinophilic esophagitis (EoE) market as a potential driver for Celldex’s future performance, maintaining confidence with an Overweight rating and a $67.00 price target. These developments underscore Celldex’s ongoing efforts in advancing its clinical programs and strategic growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.